BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19656415)

  • 1. Molecular genetics analysis of hereditary breast and ovarian cancer patients in India.
    Soumittra N; Meenakumari B; Parija T; Sridevi V; Nancy KN; Swaminathan R; Rajalekshmy KR; Majhi U; Rajkumar T
    Hered Cancer Clin Pract; 2009 Aug; 7(1):13. PubMed ID: 19656415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
    Rajkumar T; Soumittra N; Nancy NK; Swaminathan R; Sridevi V; Shanta V
    Asian Pac J Cancer Prev; 2003; 4(3):203-8. PubMed ID: 14507240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 6. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
    da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
    BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A; Dobricic J; Brankovic-Magic M
    J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
    BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer.
    Vietri MT; Molinari AM; Laura De Paola M; Cantile F; Fasano M; Cioffi M
    Clin Chem Lab Med; 2012 Dec; 50(12):2171-80. PubMed ID: 23096105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.